
The FDA approved dostarlimab in rectal cancer and pembrolizumab in tumors with high mutational burden, Europe cleared teclistamab in myeloma, and more.
Meghan Thompson, MD, discusses future research directions in chronic lymphocytic leukemia.
Meghan Thompson, MD, third-year fellow, Hematology and Medical Oncology, Memorial Sloan Kettering Cancer Center, discusses future research directions in chronic lymphocytic leukemia (CLL).
Although several therapies are available to treat patients with CLL, many patients experience disease progression, Thompson says. As such, developing a greater understanding of how to best tailor available therapies to patients is of paramount importance, Thompson explains.
Additionally, the development of improved treatment sequencing of monotherapies or combinations could further improve outcomes for patients with CLL, Thompson concludes.
